Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond
Authors:
- 1 July 2022
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 42 (42) , 366-382
Abstract
PSMA is a transmembrane protein that is markedly overexpressed in prostate cancer, making it an excellent target for imaging and treating patients with prostate cancer. Several small molecule inhibitors and antibodies of PSMA have been radiolabeled for use as therapeutic agents and are currently under clinical investigation. PSMA-based radionuclide therapy is a promising therapeutic option for men with metastatic prostate cancer. The phase II TheraP study demonstrated superior efficacy, lower side effects, and improved patient-reported outcomes compared with cabazitaxel. The phase III VISION study demonstrated that radionuclide therapy with β-emitter 177Lu-PSMA-617 can prolong survival and improve quality of life when offered in addition to standard-of-care therapy in men with PSMA-positive metastatic castration-resistant prostate cancer whose disease had progressed with conventional treatments. Nevertheless, up to 30% of patients have inherent resistance to PSMA-based radionuclide therapy, and acquired resistance is inevitable. Hence, strategies to increase the efficacy of PSMA-based radionuclide therapy have been under clinical investigation. These include better patient selection; increased radiation damage delivery via dosimetry-based administered dose or use of α-emitters instead of β-emitters; or using combinatorial approaches to overcome radioresistance mechanisms (innate or acquired), such as with novel hormonal agents, PARP inhibitors, or immunotherapy.Keywords
This publication has 148 references indexed in Scilit:
- Challenges in Recognizing Treatment-Related Neuroendocrine Prostate CancerJournal of Clinical Oncology, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Prostate Cancer ImmunotherapyClinical Cancer Research, 2011
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigenProceedings of the National Academy of Sciences, 2011
- Therapeutic efficacy of 177Lu‐CHX‐A″‐DTPA‐hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapyThe Prostate, 2008
- CD8+ Foxp3+ Regulatory T Cells Mediate Immunosuppression in Prostate CancerClinical Cancer Research, 2007
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapyJournal of Experimental Medicine, 2006
- Tumor Therapy with Targeted Atomic NanogeneratorsScience, 2001
- Low-energy Electron Emitters for Targeted Radiotherapy of Small TumoursActa Oncologica, 2001
- High-LET radiations induce a large proportion of non-rejoining DNA breaksNature, 1977